DECAMP-2: Screening of Patients With Early Stage Lung Cancer or at High Risk for Developing Lung Cancer

Active, not recruitingOBSERVATIONAL
Enrollment

665

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Pulmonary Disease
Interventions
OTHER

Biosamples from airway and blood

Identify biomarkers in biosamples from airway and blood for the preclinical detection of lung cancer.

Trial Locations (15)

14263

Health Research Inc. Roswell Park Division, Buffalo

14520

Veterans Research Foundation of Pittsburgh, Pittsburgh

19104

Trustees of University of Pennsylvania (Philadelphia VA Medical Center), Philadelphia

University of Pennsylvania, Philadelphia

20889

Walter Reed National Military Medical Center, Bethesda

23708

Naval Medical Center Portsmouth, Portsmouth

37212

Middle Tennessee Research Institute (Vanderbilt University), Nashville

75216

Dallas VA Research Corporation, Dallas

78219

San Antonio Military Medical Center, San Antonio

80220

Denver Research Institute, Denver

90073

Regents of the University of California LA (Los Angeles VA Healthcare System), Los Angeles

90095

University of California Los Angeles Medical Center, Los Angeles

92134

Naval Medical Center San Diego, San Diego

02118

Boston University Medical Center, Boston

02132

Boston VA Research Institute, Inc, Boston

All Listed Sponsors
collaborator

American College of Radiology Imaging Network

NETWORK

lead

Boston University

OTHER

NCT02504697 - DECAMP-2: Screening of Patients With Early Stage Lung Cancer or at High Risk for Developing Lung Cancer | Biotech Hunter | Biotech Hunter